Search
Dyne Therapeutics Inc
DYNAdd to Watchlist
25.180USD
-0.550-2.14%
Close 07-31 16:00（ET）Quotes delayed by 15 min
4.16BMarket Cap
LossP/E TTM
More Details of Dyne Therapeutics Inc Company
Dyne Therapeutics, Inc. is a clinical-stage neuromuscular disease company. It is discovering and advancing therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE platform, it is developing targeted therapeutics that deliver to muscle and the central nervous system (CNS). It has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. Its product candidate, DYNE-101, is being evaluated in ACHIEVE, an ongoing Phase I/II global clinical trial in patients with DM1. Its product candidate, DYNE-251, is being evaluated in DELIVER, an ongoing Phase I/II global clinical trial in patients with DMD who have mutations amenable to exon 51 skipping. Its other product candidates are DYNE-302 and DYNE-401. DYNE-302 addresses the genetic basis of FSHD.
Dyne Therapeutics Inc Info
Ticker SymbolDYN
Company nameDyne Therapeutics Inc
IPO dateSep 17, 2020
CEOCox (John)
Number of employees191
Security typeOrdinary Share
Fiscal year-endSep 17
Address1560 Trapelo Road
CityWALTHAM
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02451
Phone17817868230
Websitehttps://dyne-tx.com/
Ticker SymbolDYN
IPO dateSep 17, 2020
CEOCox (John)
Company Executives of Dyne Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. John Cox
Mr. John Cox
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
171.51K
-1.56%
Dr. Catherine Stehman-Breen, M.D.
Dr. Catherine Stehman-Breen, M.D.
Independent Director
Independent Director
89.47K
--
Dr. Oxana Beskrovnaya, Ph.D.
Dr. Oxana Beskrovnaya, Ph.D.
Chief Innovation Officer
Chief Innovation Officer
88.95K
+51.66%
Mr. Jason Rhodes
Mr. Jason Rhodes
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Edward (Ed) Hurwitz, J.D.
Mr. Edward (Ed) Hurwitz, J.D.
Independent Director
Independent Director
--
--
Mr. Dirk Kersten
Mr. Dirk Kersten
Independent Director
Independent Director
--
--
Mr. David C. Lubner
Mr. David C. Lubner
Independent Director
Independent Director
--
--
Mrs. Amy Reilly
Mrs. Amy Reilly
Senior Vice President - Corporate Communications and Investor Relations
Senior Vice President - Corporate Communications and Investor Relations
--
--
Dr. Carlo Incerti, M.D.
Dr. Carlo Incerti, M.D.
Independent Director
Independent Director
--
--
Dr. Doug Kerr
Dr. Doug Kerr
Chief Medical Officer
Chief Medical Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. John Cox
Mr. John Cox
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
171.51K
-1.56%
Dr. Catherine Stehman-Breen, M.D.
Dr. Catherine Stehman-Breen, M.D.
Independent Director
Independent Director
89.47K
--
Dr. Oxana Beskrovnaya, Ph.D.
Dr. Oxana Beskrovnaya, Ph.D.
Chief Innovation Officer
Chief Innovation Officer
88.95K
+51.66%
Mr. Jason Rhodes
Mr. Jason Rhodes
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Edward (Ed) Hurwitz, J.D.
Mr. Edward (Ed) Hurwitz, J.D.
Independent Director
Independent Director
--
--
Mr. Dirk Kersten
Mr. Dirk Kersten
Independent Director
Independent Director
--
--
FAQs
Who are the top five shareholders of Dyne Therapeutics Inc?
The top five shareholders of Dyne Therapeutics Inc are: Mr. John Cox
How many institutions hold shares of Dyne Therapeutics Inc (DYN)?
As of 2026Q1, 493 institutions hold shares of Dyne Therapeutics Inc, with a combined market value of approximately 190.35M, accounting for 115.28% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -7815975.00.